1. Home
  2. RSSS vs CRDF Comparison

RSSS vs CRDF Comparison

Compare RSSS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

SELL

Current Price

$2.14

Market Cap

71.2M

ML Signal

SELL

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.85

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RSSS
CRDF
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
67.1M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
RSSS
CRDF
Price
$2.14
$0.85
Analyst Decision
Buy
Buy
Analyst Count
3
5
Target Price
$3.75
★ $5.14
AVG Volume (30 Days)
49.9K
★ 1.0M
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 125.00
27.37
EPS
★ 0.02
N/A
Revenue
★ $28,793,922.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
N/A
P/E Ratio
$102.50
★ N/A
Revenue Growth
2.77
★ 49.61
52 Week Low
$1.77
$0.71
52 Week High
$3.38
$3.31

Technical Indicators

Market Signals
Indicator
RSSS
CRDF
Relative Strength Index (RSI) 61.18 48.53
Support Level $1.84 $0.75
Resistance Level $2.13 $1.13
Average True Range (ATR) 0.12 0.07
MACD 0.04 0.02
Stochastic Oscillator 57.14 67.42

Price Performance

Historical Comparison
RSSS
CRDF

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from the cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: